Teva downgraded at Morgan Stanley

As previously reported, Morgan Stanley downgraded Teva (TEVA) to Underweight from Equal Weight. The firm downgraded shares due to relative valuation and lower margin assumptions for Copaxone given the likelihood Mylan (MYL) will secure FDA generic approval. Note that U.S. patents for Copaxone expire in May 2014.